These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

657 related articles for article (PubMed ID: 31711752)

  • 1. Safety, pharmacokinetics, and antiviral effects of ABI-H0731, a hepatitis B virus core inhibitor: a randomised, placebo-controlled phase 1 trial.
    Yuen MF; Agarwal K; Gane EJ; Schwabe C; Ahn SH; Kim DJ; Lim YS; Cheng W; Sievert W; Visvanathan K; Ruby E; Liaw S; Yan R; Huang Q; Colonno R; Lopatin U
    Lancet Gastroenterol Hepatol; 2020 Feb; 5(2):152-166. PubMed ID: 31711752
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety, pharmacokinetics, and antiviral activity of RO7049389, a core protein allosteric modulator, in patients with chronic hepatitis B virus infection: a multicentre, randomised, placebo-controlled, phase 1 trial.
    Yuen MF; Zhou X; Gane E; Schwabe C; Tanwandee T; Feng S; Jin Y; Triyatni M; Lemenuel-Diot A; Cosson V; Xue Z; Kazma R; Bo Q
    Lancet Gastroenterol Hepatol; 2021 Sep; 6(9):723-732. PubMed ID: 34237271
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antiviral Activity, Safety, and Pharmacokinetics of Capsid Assembly Modulator NVR 3-778 in Patients with Chronic HBV Infection.
    Yuen MF; Gane EJ; Kim DJ; Weilert F; Yuen Chan HL; Lalezari J; Hwang SG; Nguyen T; Flores O; Hartman G; Liaw S; Lenz O; Kakuda TN; Talloen W; Schwabe C; Klumpp K; Brown N
    Gastroenterology; 2019 Apr; 156(5):1392-1403.e7. PubMed ID: 30625297
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
    Buti M; Gane E; Seto WK; Chan HL; Chuang WL; Stepanova T; Hui AJ; Lim YS; Mehta R; Janssen HL; Acharya SK; Flaherty JF; Massetto B; Cathcart AL; Kim K; Gaggar A; Subramanian GM; McHutchison JG; Pan CQ; Brunetto M; Izumi N; Marcellin P;
    Lancet Gastroenterol Hepatol; 2016 Nov; 1(3):196-206. PubMed ID: 28404092
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TLR7 agonist RO7020531 versus placebo in healthy volunteers and patients with chronic hepatitis B virus infection: a randomised, observer-blind, placebo-controlled, phase 1 trial.
    Yuen MF; Balabanska R; Cottreel E; Chen E; Duan D; Jiang Q; Patil A; Triyatni M; Upmanyu R; Zhu Y; Canducci F; Gane EJ
    Lancet Infect Dis; 2023 Apr; 23(4):496-507. PubMed ID: 36509100
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of the siRNA JNJ-73763989 and the capsid assembly modulator JNJ-56136379 (bersacapavir) with nucleos(t)ide analogues for the treatment of chronic hepatitis B virus infection (REEF-1): a multicentre, double-blind, active-controlled, randomised, phase 2b trial.
    Yuen MF; Asselah T; Jacobson IM; Brunetto MR; Janssen HLA; Takehara T; Hou JL; Kakuda TN; Lambrecht T; Beumont M; Kalmeijer R; Guinard-Azadian C; Mayer C; Jezorwski J; Verbinnen T; Lenz O; Shukla U; Biermer M;
    Lancet Gastroenterol Hepatol; 2023 Sep; 8(9):790-802. PubMed ID: 37442152
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety, pharmacokinetics and antiviral activity of ABI-H2158, a hepatitis B virus core inhibitor: A randomized, placebo-controlled phase 1 study.
    Agarwal K; Xu J; Gane EJ; Nguyen TT; Ding Y; Knox SJ; Alves K; Evanchik M; Zomorodi K; Ma J; Yan R; Huang Q; Colonno R; Stamm LM; Hassanein TI; Kim DJ; Lim YS; Yuen MF
    J Viral Hepat; 2023 Mar; 30(3):209-222. PubMed ID: 36302125
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preclinical Profile and Characterization of the Hepatitis B Virus Core Protein Inhibitor ABI-H0731.
    Huang Q; Cai D; Yan R; Li L; Zong Y; Guo L; Mercier A; Zhou Y; Tang A; Henne K; Colonno R
    Antimicrob Agents Chemother; 2020 Oct; 64(11):. PubMed ID: 32868329
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
    Chan HL; Fung S; Seto WK; Chuang WL; Chen CY; Kim HJ; Hui AJ; Janssen HL; Chowdhury A; Tsang TY; Mehta R; Gane E; Flaherty JF; Massetto B; Gaggar A; Kitrinos KM; Lin L; Subramanian GM; McHutchison JG; Lim YS; Acharya SK; Agarwal K;
    Lancet Gastroenterol Hepatol; 2016 Nov; 1(3):185-195. PubMed ID: 28404091
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and efficacy of vebicorvir administered with entecavir in treatment-naïve patients with chronic hepatitis B virus infection.
    Sulkowski MS; Agarwal K; Ma X; Nguyen TT; Schiff ER; Hann HL; Dieterich DT; Nahass RG; Park JS; Chan S; Han SB; Gane EJ; Bennett M; Alves K; Evanchik M; Yan R; Huang Q; Lopatin U; Colonno R; Ma J; Knox SJ; Stamm LM; Bonacini M; Jacobson IM; Ayoub WS; Weilert F; Ravendhran N; Ramji A; Kwo PY; Elkhashab M; Hassanein T; Bae HS; Lalezari JP; Fung SK; Yuen MF
    J Hepatol; 2022 Nov; 77(5):1265-1275. PubMed ID: 35697332
    [TBL] [Abstract][Full Text] [Related]  

  • 11. JNJ-56136379, an HBV Capsid Assembly Modulator, Is Well-Tolerated and Has Antiviral Activity in a Phase 1 Study of Patients With Chronic Infection.
    Zoulim F; Lenz O; Vandenbossche JJ; Talloen W; Verbinnen T; Moscalu I; Streinu-Cercel A; Bourgeois S; Buti M; Crespo J; Manuel Pascasio J; Sarrazin C; Vanwolleghem T; Shukla U; Fry J; Yogaratnam JZ
    Gastroenterology; 2020 Aug; 159(2):521-533.e9. PubMed ID: 32343960
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase 1 trial of the safety, pharmacokinetics, and antiviral activity of EDP-514 in untreated viremic chronic hepatitis B patients.
    Yuen MF; Chuang WL; Peng CY; Jeng WJ; Su WW; Chang TT; Chen CY; Hsu YC; De La Rosa G; Ahmad A; Luo E; Conery AL
    Clin Mol Hepatol; 2024 Jul; 30(3):375-387. PubMed ID: 38528825
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase IIa, randomised, double-blind study of GSK3389404 in patients with chronic hepatitis B on stable nucleos(t)ide therapy.
    Yuen MF; Heo J; Kumada H; Suzuki F; Suzuki Y; Xie Q; Jia J; Karino Y; Hou J; Chayama K; Imamura M; Lao-Tan JY; Lim SG; Tanaka Y; Xie W; Yoon JH; Duan Z; Kurosaki M; Park SJ; Labio ME; Kumar R; Kweon YO; Yim HJ; Tao Y; Cremer J; Elston R; Davies M; Baptiste-Brown S; Han K; Campbell FM; Paff M; Theodore D
    J Hepatol; 2022 Oct; 77(4):967-977. PubMed ID: 35714812
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety, tolerability and antiviral activity of the antisense oligonucleotide bepirovirsen in patients with chronic hepatitis B: a phase 2 randomized controlled trial.
    Yuen MF; Heo J; Jang JW; Yoon JH; Kweon YO; Park SJ; Tami Y; You S; Yates P; Tao Y; Cremer J; Campbell F; Elston R; Theodore D; Paff M; Bennett CF; Kwoh TJ
    Nat Med; 2021 Oct; 27(10):1725-1734. PubMed ID: 34642494
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect on HBs antigen clearance of addition of pegylated interferon alfa-2a to nucleos(t)ide analogue therapy versus nucleos(t)ide analogue therapy alone in patients with HBe antigen-negative chronic hepatitis B and sustained undetectable plasma hepatitis B virus DNA: a randomised, controlled, open-label trial.
    Bourlière M; Rabiega P; Ganne-Carrie N; Serfaty L; Marcellin P; Barthe Y; Thabut D; Guyader D; Hezode C; Picon M; Causse X; Leroy V; Bronowicki JP; Carrieri P; Riachi G; Rosa I; Attali P; Molina JM; Bacq Y; Tran A; Grangé JD; Zoulim F; Fontaine H; Alric L; Bertucci I; Bouvier-Alias M; Carrat F;
    Lancet Gastroenterol Hepatol; 2017 Mar; 2(3):177-188. PubMed ID: 28404133
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and efficacy of vesatolimod (GS-9620) in patients with chronic hepatitis B who are not currently on antiviral treatment.
    Agarwal K; Ahn SH; Elkhashab M; Lau AH; Gaggar A; Bulusu A; Tian X; Cathcart AL; Woo J; Subramanian GM; Andreone P; Kim HJ; Chuang WL; Nguyen MH
    J Viral Hepat; 2018 Nov; 25(11):1331-1340. PubMed ID: 29851204
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Three year adefovir dipivoxil treatment for hepatitis B e antigen-positive chronic hepatitis B patients].
    Ling N; Zhou Z; Zhang DZ; Ren H
    Zhonghua Gan Zang Bing Za Zhi; 2007 May; 15(5):346-9. PubMed ID: 17524266
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of tenofovir disoproxil fumarate in hepatitis B e antigen-positive patients with normal levels of alanine aminotransferase and high levels of hepatitis B virus DNA.
    Chan HL; Chan CK; Hui AJ; Chan S; Poordad F; Chang TT; Mathurin P; Flaherty JF; Lin L; Corsa A; Gaggar A; Subramanian GM; McHutchison JG; Lau G; Lee S; Gane EJ
    Gastroenterology; 2014 May; 146(5):1240-8. PubMed ID: 24462735
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oral prenylation inhibition with lonafarnib in chronic hepatitis D infection: a proof-of-concept randomised, double-blind, placebo-controlled phase 2A trial.
    Koh C; Canini L; Dahari H; Zhao X; Uprichard SL; Haynes-Williams V; Winters MA; Subramanya G; Cooper SL; Pinto P; Wolff EF; Bishop R; Ai Thanda Han M; Cotler SJ; Kleiner DE; Keskin O; Idilman R; Yurdaydin C; Glenn JS; Heller T
    Lancet Infect Dis; 2015 Oct; 15(10):1167-1174. PubMed ID: 26189433
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial.
    Gane EJ; Roberts SK; Stedman CA; Angus PW; Ritchie B; Elston R; Ipe D; Morcos PN; Baher L; Najera I; Chu T; Lopatin U; Berrey MM; Bradford W; Laughlin M; Shulman NS; Smith PF
    Lancet; 2010 Oct; 376(9751):1467-75. PubMed ID: 20951424
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.